Q-omics provides the consensus-scored RAB15 profile across patient tissues and cancer cell-line models. RAB15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAB15 is differentially expressed in 15, with the highest sampling consensus in LUAD. Additionally, RAB15 RNA expression shows 21,074 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LUAD as cancer lineages where RAB15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB15 survival associations across molecular data types. RAB15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB15 RNA expression–survival associations across cancer types. High RAB15 expression shows unfavorable associations in ACC, UVM, MESO, KIRP, KIRC and ESCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAB15 RNA expression.
This table summarizes RAB15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB15 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, COAD, THCA and STAD. The LUAD box plot shows higher RAB15 RNA expression in tumor versus normal tissue (log2 FC = +2.255, t-test p < 0.001).
This table shows molecular features associated with RAB15 in patient tissues and cancer cell lines. In patient samples, RAB15 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
